Effexor is the brand name for venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI). It's FDA-approved for major depression, generalized anxiety disorder, social anxiety disorder, and panic disorder. The therapeutic effect on anxiety develops over four to six weeks at typical doses of 75 to 225 mg per day. Its discontinuation syndrome is more pronounced than with SSRIs and requires a slow taper.
What Effexor is
Effexor is the brand name for venlafaxine, a medication in the SNRI class. It's typically prescribed as Effexor XR, the extended-release formulation that allows once-daily dosing. Venlafaxine was approved by the FDA in 1993 for major depressive disorder; it has since been approved for generalized anxiety, social anxiety disorder, and panic disorder. Generic venlafaxine and venlafaxine XR are widely available. The MedlinePlus drug information page for venlafaxine covers the patient-facing essentials.
The longer reference for the SNRI class is SNRIs explained, which describes the mechanism and the differences between venlafaxine, duloxetine, and the rest of the class.
What it does
Venlafaxine blocks reuptake of both serotonin and norepinephrine. At lower doses (under about 150 mg) the effect is predominantly serotonergic and resembles an SSRI. At higher doses the norepinephrine effect becomes more prominent. The norepinephrine component is what differentiates SNRIs from SSRIs and is one reason patients with prominent fatigue sometimes do better on an SNRI than on an SSRI alone. You can see what an SNRI does at the synapse in PsychiatryRx's interactive guide.
The therapeutic effect on anxiety develops over weeks. As with SSRIs, the felt change isn't from the dose taken in the morning; it's from the cumulative adaptation of threat-detection circuitry over time.
What it feels like
Patients on a working dose of Effexor describe the same general arc as on an SSRI: worry softens, sleep often consolidates, physical tension comes down. Energy is sometimes a little higher than on an SSRI, which is partly the norepinephrine effect.
Early side effects in the first weeks include nausea, headache, sleep disruption (sometimes insomnia, sometimes sedation), sweating, and dry mouth. Sweating, in particular, is more common with SNRIs than SSRIs and can persist. Sexual side effects are common.
When it's chosen
Effexor is often chosen for:
- Generalized anxiety disorder when an SSRI hasn't produced enough response
- Patients with prominent fatigue, where the norepinephrine effect may help
- Panic disorder when SSRIs haven't been tolerated
- Patients with co-occurring chronic pain (though duloxetine has stronger pain indications)
It's less often chosen as a first-line agent because its discontinuation syndrome is more pronounced than with SSRIs and because its blood pressure effect at higher doses requires monitoring.
Typical dosing and timeline
Starting dose is typically 37.5 mg or 75 mg daily of the extended-release form, taken in the morning with food. After one week, the dose is usually increased to 75 mg. The typical effective dose is 75 to 225 mg daily. The FDA-approved maximum is 225 mg for generalized anxiety; higher doses are used in depression. Above 150 mg, blood pressure monitoring is reasonable.
The therapeutic effect on anxiety develops over four to six weeks at a stable dose.
Side effects and cautions
Sweating, sexual dysfunction, and modest dose-dependent blood pressure elevation are the most distinctive side effects compared with the SSRIs. Nausea and headache in the first two weeks are common and usually settle. Discontinuation syndrome is the most distinctive concern: dizziness, electric-shock sensations, flu-like symptoms, and irritability are common with abrupt stopping or even with missed doses.
The NIMH overview of mental health medications discusses the SNRI class in patient-facing terms. The FDA boxed warning on increased suicidal thoughts in patients under 25 in the first months of treatment applies to SNRIs as well as SSRIs.
What Effexor doesn't do
Effexor doesn't produce an immediate calming effect. As with all serotonergic antidepressants, the therapeutic action comes from weeks of receptor adaptation, not from individual doses.
Effexor isn't a controlled substance and doesn't produce addiction. It does produce physical adaptation, which is why it requires a slow taper, often over weeks to months, to stop without significant discontinuation symptoms.
Comparison with related medications
Compared with duloxetine, venlafaxine has more dose-related blood pressure effect and a more pronounced discontinuation syndrome; duloxetine has stronger indications in chronic pain conditions. See the Effexor vs Cymbalta comparison. Compared with SSRIs such as Lexapro or sertraline, venlafaxine has a similar therapeutic timeline but a harder discontinuation course and the norepinephrine effect.